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Abstract

20

25

30

The study of the interaction of anticancer drugs with mammalian cells in vitro is important to elucidate the mechanisms of action of the
drug on its biological targets. In this context, Raman spectroscopy is a potential candidate for high throughput, noninvasive analysis. To
explore this potential, the interaction of cis-Diamminedichloroplatinum (II) (Cisplatin) with a human lung adenocarcinoma cell line
(A549) was investigated using Raman microspectroscopy. The results were correlated with parallel measurements from the MTT
cytotoxicity assay, which yielded an IC50 value of 1.2±0.2 μM. To further confirm the spectral results, Raman spectra were also acquired
from DNA extracted from A549 cells exposed to cisplatin and from unexposed controls. Partial least squares (PLS) multivariate
regression and PLS Jack-knifing were employed to highlight spectral regions which varied in a statistically significant manner with
exposure to cisplatin and with the resultant changes in cellular physiology measured by the MTT assay. The results demonstrate the
potential of the cellular Raman spectrum to non-invasively elucidate spectral changes that have their origin either in the biochemical
interaction of external agents with the cell or its physiological response, allowing the prediction of the cellular response and the
identification of the origin of the chemotherapeutic response at a molecular level in the cell.

Introduction

For the design of new anticancer drugs, an in-depth
understanding of the mechanisms underlying their
biological effects is required. It is therefore of interest to
35 understand details of the molecular and biochemical
mechanisms associated with the biological activity of
existing commercial anti-cancer agents. The potential of
confocal Raman microspectroscopy (CRM) for the
analysis of biological tissue1 and the effect of external
2-6
40 agents on the cell
has been demonstrated. CRM is noninvasive, cost effective, rapid and requires no sample
labelling prior to analysis7. The technique, with its
counterpart Fourier transform infrared microspectroscopy,
has great potential to explore sub-cellular biochemical
45 structure as exemplified by its use in studies investigating
the action of various agents on biological macromolecules
as well as their interaction with cancer cells7-13.
Validation of CRM in the quantitative measurement of the
biochemical and physiological effects of known
chemotherapeutic agents is required before it may be used
for studies of novel chemical treatments. Cisplatin (cisDiamminedichloroplatinum (II)) is a well established
chemotherapeutic agent with a known mode of action. In
55 the nucleus, it binds with DNA forming inter-strand and
50
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intra-strand crosslinks which lead to cell cycle arrest and
apoptosis14. The formation of inter-strand and intra-strand
crosslinks between cisplatin and DNA leads to
conformational changes of the DNA. To understand the
changes caused in DNA conformation due to the adducts
formed by cisplatin, the formation of 1,2-GG or 1,3-GTG
cross-links and their characterization by
65 intra-strand
Raman spectroscopy has been carried out15 and it was
found that 1,3 GTG cross linkages induce more distortion
in the B-form DNA as compared to the 1,2-GG complex.
60

The aim of the current study is to evaluate the quantitative
predictive capabilities of CRM in the elucidation of the
mode of action of chemotherapeutic agents, using cisplatin
and A549 adenocarcinoma cells as a model compound and
test system respectively. Spectra of the cellular nuclei were
75 taken after a 96 hour exposure period to the agent, and
multivariate models of the variation in spectral content
with levels of exposure and with degrees of
cytotoxicological response were constructed. A feature
selection technique was then used to identify regions of the
80 spectrum that were associated with the biochemical effect
of exposure to the agent, and with the subsequent
cytotoxicological response of the cells. It is demonstrated
70
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that the CRM data, in conjunction with multivariate
modeling, is capable of identifying spectral signatures of
both the biochemical action and physiological response to
exposure to the chemotherapeutic agent, and that the
5 measurement may be used in predicting both responses in
cancer cells.

Materials and methods
10

Cell culture

A549 human lung adenocarcinoma cells were obtained
from ATCC (CCL-185). The cells were cultured in DMEM
F-12 (Sigma Aldrich, Ireland) medium supplemented with
10% FBS, 1μg/ml hydrocortisone (Sigma), 2mM L(Gibco) and 1% penicillin- streptomycin
15 glutamine
(Gibco). Cells were incubated at 37°C in 5% CO2 and
routinely subcultured with 1:1 ratio of 0.25% trypsin and
0.1% EDTA when they reached 70-80% confluency.
20

Cytotoxicity assay

Cisplatin, obtained from Sigma Aldrich, Ireland, was
dissolved in 1% NaCl (Sigma Aldrich, Ireland) solution
(pH 7) to prepare the stock solution. Working solutions of
the drug were prepared in cell culture media. MTT [3-(4,5tetrazolium bromide]
25 dimethylthiazol-2-yl)-2,5-diphenyl
was obtained from Sigma Aldrich, Ireland. The MTT assay
was performed in triplicate according to a method reported
previously16, 17 with a slight modification. MTT is a yellow
coloured molecule that is converted to purple formazan by
reductases in living cells, and thus
30 mitochondrial
measurements of its absorbance are indicative of the level
of cellular metabolic activity and the consequent levels of
DNA repair activity and cell death after exposure to
Cisplatin. A 96-hour exposure period to Cisplatin was
35 chosen along with a wide range of exposure concentrations
as this provided a wide range of measurements of degrees
of cytotoxicity with which to challenge the predictive
ability of the Raman spectral measurement.
The MTT measurement protocol was as follows. Cells
were cultured in 96-well plates (Nunc, Denmark) at a
density of 2  103 cells per well in DMEM-F12 medium
with all the supplements as listed above. After 24 hrs of
initial cell attachment, the plates were washed with 100
45 μl/well phosphate buffered saline (PBS) and were treated
with varying concentrations of cisplatin in the range from
0.05 μM- 50μM (including a separate unexposed control
sample). Following a 96-hour exposure period, the cells
were rinsed with PBS and 100 μl of fresh medium (without
50 supplements) were added to each well. A volume of 10l
of MTT (5mg/ml) prepared in PBS was then added to each
well and the plates were incubated for 3 hrs16 at 37 °C in a
5% CO2 humidified incubator. After this incubation period,
the medium was discarded, the cells were washed with 100
55 μl of PBS and 100 μl of DMSO were added to each well to
extract the dye. The plates were then shaken 240 times per
minute for 10 min and the absorbance was measured at 570
40
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nm using a micro plate reader (Tecan Genios, Grodig,
Austria). Six replicate wells were used for each exposure.
60

Sample preparation for Confocal Raman Microspectroscopy

For CRM, cell samples were cultured on quartz substrates
according to a protocol outlined elsewhere6. Briefly, quartz
coverslips were coated with a 2% w/v gelatin-water
65 solution and maintained at 4 °C for 6 hrs to allow
polymerization of the gelatin to the substrate.
Subsequently, 2.5  103 A549 cells were attached to the
substrates for a 48 hour period, and were exposed to the
cisplatin concentrations employed for the cytotoxicity
70 assay for a 96-hour period (together with a non-exposed
control sample). After the exposure period, the cells were
fixed in 4% formalin for 10 minutes and were stored in 0.9
% physiological saline solution at 4 °C until the Raman
analysis was performed. All samples were prepared in
75 triplicate.
DNA extraction

The cellular DNA was extracted from both a control
sample of A549 cells together with a sample of A549 cells
80 exposed to 3 μM cisplatin for 96 hours. As determined
using the cytotoxicity assay, at this concentration, the
viability has reduced to approximately 30% and thus it
represents the 1/e point of the response. Briefly, cells were
trypsinised and centrifuged to form a pellet of cells, and 1
6
85 ml TRIzol reagent (Invitrogen) per 5 - 10  10 cells was
added. The samples were then homogenized and incubated
at room temperature for 5 min to induce cell lysis. For each
ml of TRIzol reagent, 200 μl of chloroform was added and
samples were centrifuged at 12,000 × g for 5 min at 4 °C.
90 Following centrifugation, the mixture separated out into a
lower red organic phase, a thin interphase and a colourless
upper aqueous phase. The DNA was precipitated from the
interphase and organic phase with 300 μl of 100% ethanol
per ml of TRIzol reagent. Once precipitated, the DNA was
95 washed twice in a solution of 0.1M trisodium citrate in
10% ethanol. The DNA was then dissolved in dH2O as
water has a significantly weaker Raman signal than
common organic solvents. Samples were mixed by
inversion, left at room temperature for 2–3 min and then
100 centrifuged at 2,000 × g for 5 min at 4 °C. The DNA pellet
was recovered and maintained at −20 ◦C until analysis. To
ensure the purity of the DNA, the absorbance of the sample
was recorded on a UV-Vis spectrophotometer according to
the manufacturer’s protocol.
105

Spectral Acquisition

CRM was conducted with a Horiba Jobin-Yvon, LabRam
HR800 instrument using a 785 nm laser as source. The
110 laser power was approximately 70 mW at the sample.
Spectra were taken in the range from 600 cm-1 to 1800 cm1
with a confocal hole diameter of 100μm. A 100 water
immersion objective was used to focus the laser on the
sample, immersed in 0.9% saline, yielding a spot size of
115 ~1m. Multiple spectra were recorded from the nuclear

This journal is © The Royal Society of Chemistry [year]

portion of a total of 60 cells at each exposure level.
Subsequently the spectra were filtered with a SavitskyGolay filter (order 5, 13 point window), and the quartz
signal background was subtracted using algorithms
5 developed in-house. Prior to analysis the spectra were also
vector normalized. For the acquisition of the spectra from
the extracted DNA, the DNA solution was drop cast onto
quartz substrates. The Raman spectrum of pure cis-platin
was measured in the raw powder form.

60

72 hrs, IC50 values of 3.59 μM and 2.2 μM are reported
elsewhere with MTT and ATP assays respectively26. Also,
Cordes et al. have determined an IC50 value of 2.0 μM for
cisplatin (0.1-50 μM) exposed A549 cells using the colony
formation assay27.

10

Data analysis

All spectral analysis was performed in the Matlab 7.2 (The
Mathworks Inc.) environment employing the PLS Toolbox
(Eigenvector Research, Wenatchee, WA) and
15 5.0.3
algorithms developed in-house. Outlying spectra were
removed using Grubb’s filtering18. All spectra, including
calibration and substrate backgrounds, were vector
normalized. The substrate spectra were subtracted from
20 each spectrum and a fifth order polynomial was fitted to
the spectra to remove any residual spectral baseline.
Multivariate regression models were constructed using
Partial Least Squares Regression (PLSR)19 and PLS Jackknifing was employed as a multivariate feature selection
5, 20, 21
25 technique
. The PLSR algorithm seeks to develop a
model that relates the spectral data (X-matrix) to a series of
targets (Y-matrix, e.g. concentration of reaction product or
analyte) according to the equation Y=XB+E, where B is a
matrix of regression coefficients and E is the regression
30 residual. The Y-matrix here consisted of values of the
concentration of cisplatin to which the cell was exposed, or
the measured level of cell viability from the MTT assay.
The PLS Jack-knifing method developed by Westad and
Martens21 was then used to determine the spectral features
35 that were statistically significant at a particular level of
confidence using t-testing of the regression coefficients, B.
The Raman band assignments used in the interpretation of
the spectral features were taken from the literature6, 22-25.
40

65

Figure 1. A549 cell viability (measured by MTT absorption) at 96 hours
after exposure to Cisplatin. Error bars denote the standard error on the
mean at each concentration.

Raman Spectrum of Cisplatin
70

The Raman spectrum of pure cisplatin is shown in Figure
2. The most prominent features lie in the region between
100-550 cm-1 28, which does not fall within the 600-1800
cm-1 spectral window of the current measurements and
75 therefore they do not contribute to the cellular spectrum.

Results and Discussion
Cytotoxicity assay

The MTT assay is a measure of the mitochondrial
metabolic activity and in the current study is used initially
45 as a standard against which to map the response as
measured by CRM. Maximum cytotoxicity was observed
after 96hrs exposure and thus this time period was
employed for all measurements. The cytotoxicity induced
in A549 cells due to the exposure to cisplatin for 96hrs, as
50 determined by the MTT assay, is shown in Figure 1,
where the level of viability in each sample was normalised
to that in the control sample. Due to the action of the drug,
the mitochondrial activity decreases monotonically which
in turn leads to a decrease in cell viability. The Inhibitory
55 Concentration (IC50) value was derived from the data by a
fit of f(x) = min + (max-min)/(1+(x/IC50)^n) and found to
be 1.2 ± 0.2μM, which is consistent with the literature. For
A549 cells exposed to test drug concentration (TDC) for
This journal is © The Royal Society of Chemistry [year]

Figure 2. Raman spectrum of cisplatin powder
80

Nuclear spectral features

Figure 3A shows the mean control spectra of the nucleus
of A549 cells. The Raman bands which are important and
in which changes due to the action of cisplatin may be
-1
85 expected are labelled. The Raman bands at 669 cm
and
-1
1375 cm can be assigned to thymine and at 1336 cm-1 to
guanine. Two bands at 807 cm-1 and 833 cm-1 are assigned,
respectively, to the O-P-O stretching of the DNA-A and -B
forms and the peak at 1095 cm-1 is assigned to the O-P-O
90 stretching
of the DNA backbone in general. Other
Journal Name, [year], [vol], 00–00 | 3

Figure 3. Mean spectrum of the nucleus of control sample (A) and the difference spectrum (B) between the mean of the control and the
sample exposed to 3M cisplatin. The shaded area around each trace defines the standard error on the mean.

Figure 4 Raman spectra of DNA extracted from A549 cells exposed to 3 µM cisplatin for 96 hrs; Mean control and exposed spectra (A) and
difference spectrum (B). The extent of each trace defines the mean spectrum plus the standard error on the mean (which are very small and thus
invisible in most instances).

10
5
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prominent Raman bands derive from C-H deformation of
lipids (1449 cm-1) and the amide-I band for proteins (1660
cm-1). Lipid peaks (1480-1420 cm-1) in the nuclear spectra
may originate from contributions of the surrounding
8, 23
5 cytoplasm
.

conformational changes caused in the DNA by cisplatin
binding, high mobility group proteins bind to the site
where the cisplatin molecule has bound to the DNA and
prevent repair by nuclease enzyme excision31.
35

Spectral features of extracted nuclear DNA

Figure 3B shows the mean difference spectrum of the
nucleus of A549 cells exposed to 3 M cisplatin versus its
control. The major changes observed are labelled. The
-1
10 bands for DNA bases including thymine (at 669cm
and
-1
-1
1375 cm ) and guanine (1336 cm ) are significantly
changed due to the binding of the cisplatin. As the cisplatin
can form two types of intrastrand crosslinks, 1,2 GG and
1,3 GTG, the Raman spectral changes (i.e. to the Raman
15 bands of the Guanine(G) and thymine(T)) may indicate the
presence of both types of crosslinkages due to the action of
the cisplatin.15 The bands associated with the DNA-A and
–B form are seen to change in intensity, the B-form band at
833 cm-1 to a much greater degree. This could be indicative
20 of the induction of conformational changes in the B-form
of DNA due to the formation of intra-strand crosslinkages
of the cisplatin with guanine and adenine and binding with
thymine. This represents a Raman marker of the binding of
cisplatin with the DNA bases. The changes observed in the
-1
25 bands for the O-P-O backbone of DNA, at 1095 cm , can
be a marker for the changes in the electrostatic
environment of the phosphate group29, 30.
Changes in the bands at 1032 cm-1 (C-H stretching), 1128
(C-N stretching) and 1660 cm-1 (amide-I), are related to
30 protein structure. This may be due to the fact that after the

In order to further confirm the Raman markers for the
known mechanism of action of the cisplatin, the spectra
40 recorded of the DNA extracted from the control and
exposed (3 µM for comparison to the spectroscopic
analyses of the cells) A549 cells were analyzed. The mean
control and the difference spectra of the extracted DNA are
shown in Figure 4A and Figure 4B respectively. The
45 DNA extracted from the unexposed control and the cisplatin exposed samples were measured under identical
conditions and thus it is concluded that the spectral
differences are due to the cis-platin exposure alone, rather
than the laser.
50 Changes in the Raman bands of the DNA bases are
observed, as expected, including guanine (1180 cm-1, 1335
cm-1, 1450 cm-1, 1484 cm-1, 1578 cm-1), thymine (746 cm-1,
1242, 1375) and adenine (1307 cm-1). Changes in the
bands related to the DNA backbone, deoxyribose ring
(881 cm-1) and phosphodioxy stretching
55 breathing
vibrations (1098 cm-1) are also observed, indicative of the
conformational changes caused in the DNA by the
cisplatin action.
60

Figure 5. Calibration (A) and test set performance (B) in prediction with PLSR of the cell viability using Raman spectra of the nucleus of A549 cells. Root
mean squared errors of calibration (RMSEC) and prediction (RMSEP) are in units of cell viability, which themselves are normalized to the level in the
control.

This journal is © The Royal Society of Chemistry [year]
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Prediction of exposure level and cellular viability with PLSR

CRM can clearly fingerprint the effects of the interaction
of the chemotherapeutic agent with DNA, and identify that
5 fingerprint within the cellular spectra of exposed cells.
PLSR models of A549 nuclear spectra versus
concentration and reference viability measurements from
the MTT assay were constructed to determine the ability of
the spectral data to predict the level of exposure to
10 cisplatin and the associated level of physiological effect
from Raman spectra. All spectra were compiled into a
matrix, and were randomly sorted. A total of 60% of the
spectra were used to train the PLSR regression model and
of the total was retained as an independent test set to assess
15 the performance of the model in predicting the level of
exposure, and the cellular viability, with unseen data.
Leave-one out cross validation with the calibration set was
used to determine the optimal model complexity for use in
testing32. This process was performed on fifty separate
20 occasions, with randomization of the data matrix and
splitting of the data on each occasion to prevent data bias19.
An example of the results of prediction of levels of cellular
viability is shown in Figure 5, where the values of the root
mean square error of calibration (RMSEC) and the root
25 mean square error of prediction (RMSEP) denote the
prediction uncertainty. The mean values of the RMSEC
and RMSEP for the PLSR for prediction of the level of
exposure to cisplatin were found to be 1.67 M (0.45) and
3.41 M (0.41) respectively, where the figures in brackets
30 denote the standard deviations of these estimates. The
associated values of RMSEC and RMSEP for PLSR

against normalized cellular viability were 0.05 (0.008) and
0.11 (0.011) respectively. The RMSEP for prediction of
cisplatin concentration is therefore 6.8% over the full scale
35 range (0 to 50 M), and 11% over the full scale range of
viability (from 0 to 1). The proportionally higher observed
errors of prediction of cell viability may be due to the
development of cellular resistance to cisplatin over the
exposure period in the low dose groups33, 34, which
40 contributes to a non-linearity in the variation in viability
with concentration that is difficult for the PLSR algorithm
to model.
Feature Selection by PLS Jack-knifing
45

The spectral changes observed in Figure 2 are multivariate
and may have complex exposure dependence. It has been
demonstrated that they include the fingerprint of the
interaction of the cisplatin with the nuclear DNA, but also
50 evident are a multitude of other changes associated with
exposure and changes in cellular physiology. In an effort to
identify the most important spectral features, feature
selection was performed using a Partial Least Squares –
Jack knifing analysis described earlier. The regression co55 efficients were obtained by PLS-Jack knifing for separate
regressions against cisplatin concentrations and against cell
viability with the nuclear spectral data. To elucidate
spectral changes that are most statistically significant with
respect to regression against either endpoint, a t-test
60 (p<0.001) was applied on the PLS-Jack knifing results,
where the spectral features identified by this process are
highlighted by vertical bands in Figure 6.

Figure 6. Feature selection in PLSR of Raman spectra of the A549 nucleus against (A) cisplatin concentrations and (B) against cellular
viability. The shaded areas denote statistically significant features selected using PLS Jack-knifing with a t-test (p<0.001) of regression
coefficients (shown in red with associated standard error).
6 | Journal Name, [year], [vol], 00–00
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The PLS regression of the nuclear data against cisplatin
concentration (Figure 5A), identifies many features but for
the purpose of this discussion only the changes which are
related to the known action of cisplatin are highlighted.
-1
5 Features identified include the thymine (737-742 cm ,
-1
-1
1589-1595 cm ), guanine (1548-1553 cm ) and adenine
(1578 cm-1, 1604-1611 cm-1) bands. The regression coefficients of guanine and thymine are stronger than that of
adenine indicating that cisplatin binds preferably with
35
10 guanine as compared to adenine . Another interesting
observation is that the bands at (877-883 cm-1) and at (899900 cm-1) both assigned to deoxiribose ring breathing, are
significantly changed, which lead to a change in the
conformation of B-form DNA36-38. Changes in the Raman
15 bands of the proteins are also highlighted, as indicated by
the regression co-efficients which can be assigned to
tryptophan ring breathing (761-765 cm-1), (889-891 cm-1),
C-N stretching (1128-1132 cm-1), C-H deformation (13151316 cm-1, 1351-1354 cm-1), amide-I (1668-1679 cm-1).
20 These changes may indicate some structural changes in the
nuclear proteins.
The regression against cell viability (Figure 5B), shows the
features which are changed significantly due to the change
25 in cell physiology. These include the conformational
changes of the DNA B-form (832-833 cm-1) and DNA Aform (798-813 cm-1). These changes in the Raman bands of
the DNA can be taken as markers for the conformational
changes in the DNA caused by cisplatin binding to the
15
30 guanine and thymine DNA bases
and also confirm the
observations from the mean difference spectra. Changes
related to protein secondary and tertiary structures are
indicated by the selection of amide-III random coil (12251228 cm-1), amide-III β-sheet (1250-1259), amide-III alpha
-1
35 helix, tryptophan ring breathing (711-721 cm , 758-763
-1
-1
cm , 767-772 cm ) and phenyl ring stretching modes
(1202-1210 cm-1) together with the C-C skeletal vibrations
(935-937 cm-1, 1159-1163 cm-1), C-N stretching vibrations
(1065-1068, 1073-1075) and C-H bending (1178-1182 cm1
-1
40 ) (1185-1186 cm ). These features suggest changes in the
Raman bands of proteins and are indicative of structural
alterations associated with protein activation and
denaturation during cellular apoptosis and nucleic acid
repair responses.
45

Comparing the regression co-efficients obtained via
spectral regression against cisplatin concentration (which
highlight the primary biochemical effect of the action of
the agent) with those obtained via regression against cell
50 viability (which highlight biochemical markers of the
change in the viability of the cell), very different spectral
features are selected as being statistically significant and
thus allow the differentiation of the chemotherapeutic
response. The spectral features of thymine (737-742 cm-1,
-1
-1
55 1589-1595 cm ), guanine (1548-1553 cm ) and adenine
-1
-1
(1578 cm , 1604-1611 cm ) feature prominently as a
result of regression against the concentration of the
chemotherapeutic agent and are attributable to direct

This journal is © The Royal Society of Chemistry [year]

binding of the cisplatin molecule with these DNA bases. In
addition, changes related to proteins feature in the
regression
against
the
concentration
of
the
chemotherapeutic agent are significantly different than
those changes of protein associated bands which appear as
a result of regression against the cellular viability. The
65 changes in the features of the proteins due to the chemical
effect are attributable to structural changes in nuclear
histone proteins due to cisplatin interactions with the
cellular DNA. These features are not selected as being
statistically significant by the analysis for regression
70 against the viability endpoint, suggesting that they are
markers of the biochemical interaction between cisplatin
and DNA. Contrastingly, the conformational changes to
the DNA A-form (798-813 cm-1) and DNA B-form (832833 cm-1), among the changes associated with the protein
75 features, especially the amide-III random coil (1225-1228
cm-1), amide-III β-sheet (1250-1259), amide-III alpha
helix, among others, are selected as being statistically
significant in the regression against cellular viability
suggesting that they are markers of this physiological
80 endpoint in the chemotherapeutic response. Overall, Figure
5 demonstrates that the Raman spectrum of the cell may be
resolved into distinct groups of statistically significant
spectral markers for distinct types of effect.
60

“The study demonstrates the potential of commercially
available benchtop CRM for the examination and
prediction of chemotherapeutic responses. In general, for
subcellular resolution, Raman spectroscopy is chosen over
infrared spectroscopy due to the intrinsically higher spatial
90 resolution. Furthermore, the relative insensitivity to water
renders live cell imaging of real time exposures a
possibility39. Nonlinear optical imaging techniques40
promise even higher spatial resolution in the future, but at
present such short pulse systems cannot be considered
95 benchtop techniques.”
85

Cisplatin, a DNA major groove binder41, was chosen as a
model as its mechanism of action is well characterised. To
fully validate the technique, the study should be extended
100 to other chemotherapeutic agents of known interaction
mechanisms, such as tallimustine, a known DNA minor
groove binder, and ethidium bromide, a known DNA
intercalator. In this way the spectroscopic signatures of
their interaction can be established and subsequently can
105 act as a database against which novel chemotherapeutic
agents can be evaluated. Ultimately, the techniques should
be validated in tumour tissue.
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